Personalizing Risk Assessment and Treatment Decisions in Cancers

Smith Yoav, HUJI, School of Medicine - IMRIC



No two cancers are the same, and it can be difficult to predict which tumors are slow-growing and which are likely to grow and spread to other parts of the body. Current medical society guidelines rely on cancer stage to determine cancer treatment. Conventional classification of cancer stages is based primarily on the size and location of the tumor and serves as an indicator of disease progression.

However, cancer stage alone does not reveal the aggressiveness of the tumor. In fact, two patients with the same cancer stage may have very different estimates of mortality risk when tumor aggressiveness is taken into account.

Our Innovation

The proprietary custom made prediction kit for the aggressiveness of a tumor assessing:

  • five-year risk of cancer-specific death
  • odds of metastasis to other organs
  • treatment type, intensity and duration

 A unified method for the diagnosis and treatment of cancer based on the Expression of the Cancer Testis Antigen gene (CTA) Family in Individuals.

The Technology

The technology is based on identifying the expression signature of a unique set of genes of the Cancer Testis Antigen (CTA) Family within the tumor and applying a specially designed machine learning algorithm which applies a unique subset of CTA genes for each solid tumor type.

Application of our technology in over 15,000 individuals and more than 150 types of cancers has consistently demonstrated that it is sufficient to determine the existence and staging of all solid cancers tested, with almost perfect accuracy.

The Opportunity

The technology provides several scores for a specific tumor such as:

  • Staging, grading and tumor dynamics
  • Prediction of Overall Disease Free (ODF) and Overall Survival (OS) terms
  • Probability of metastasis to nearby glands
  • Treatment urgency
  • Estimation for treatment impact
  • Potential treatment targets

Future development may enable similar readouts using a blood test (vs. biopsied materials). Also, our technology enables identification of the most relevant CTA’s for targeting antibodies and potentially T-cells in a specific manner to the tumor.

Current Development Stage

TRL4 biopsies validated in cancer patients 

Contact for more information:

Mel Larrosa
VP Business Development Healthcare
Contact ME: